Skip to main content
OpenTrials
Completed

NCT Number: NCT07307352

25010 - ABL90 FLEX PLUS - Precision Capillary Adult - Clinical Study Protocol

Conducting the ABL90 FLEX PLUS Clinical Precision Study for 15 Parameters in Adult Whole Blood is to validate performance claims for precision in heparinized whole blood for 15 parameters: pH, pCO2, pO2, cCa2+, cCl-, cK+, cNa+, cGlu, cLac, ctHb, sO2, FO2Hb, FMetHb, FCOHb, and FHHb, while being influenced by testing environment that is representative of intended use environment, site variability, and operator variability in a point-of-care (POC) setting.

The investigational device is the ABL90 FLEX PLUS incl. consumables, running SW3.5 MR2, manufactured by Radiometer Medical ApS The study is being conducted in Denmark and in total, a minimum of 30 subjects are to be enrolled to provide successful measurement values from 2 sites.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hvidovre Hospital, Hvidovre, Denmark

Loading trial locations.

About this study

Adult Whole Blood is to validate performance claims for precision in heparinized whole blood for 15 parameters: pH, pCO2, pO2, cCa2+, cCl-, cK+, cNa+, cGlu, cLac, ctHb, sO2, FO2Hb, FMetHb, FCOHb, and FHHb, while being influenced by testing environment that is representative of intended use environment, site variability, and operator variability in a point-of-care (POC) setting.

Capillary blood collected into 2 capillary tubes from 2 distinct finger sticks will be measured on ABL90 FLEX PLUS in the Capillary mode (C65).

The study is designed to collect approximately 30 pairs of samples combined across sites.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The subject must be 18 years or older.
  • Subjects must be able to understand given information and demonstrate willingness and ability to voluntarily give a signed, valid written informed consent to participate in the study.
  • Subject evaluated as suitable according to the protocol to enroll in the study by the principal investigator or designee

Exclusion criteria

  • Subject where sample collection is evaluated by principal investigator or designee to impose an unnecessary risk.
  • Subject, with known pregnancy or breastfeeding.
  • Subject, who has an invalid written informed consent or has withdrawn consent.
  • Subjects who have been previously enrolled in the study.
  • Subjects exposed to following substances within the last 72 hours:
  • Acetylsalicylic Acid Sodium Salt at dose equal or above 1 gram/day
  • N-acetylcysteine o Fluorescein dye o Patent Blue dye -

Treatment and study plan

ABL90 FLEX PLUS analyser running SW3.5 MR2.

Diagnostic Test

The ABL90 FLEX PLUS analyzer is a portable, automated analyzer that measures pH, blood gases, electrolytes, metabolites, and oximetry in whole blood - utilizing 3 measuring modes (syringe, short probe, and capillary mode) to measure samples from a syringe, test tube or a capillary tube. The analyzer provides results for 17 parameters in 35 seconds using 65 μL heparinized whole blood.

Primary outcomes

  1. Within sample precision for each parameter measured in capillary mode pooled across sites.

    Time frame: 1 hour

    Within sample precision of each parameter (pH, pCO2, pO2, cCa2+, cCl-, cK+, cNa+, cGlu, cLac, ctHb, sO2, FO2Hb, FMetHb, FCOHb and FHHb) using replicate measurements from heparinized whole blood samples measured by intended users in a POC setting.

Secondary outcomes

  1. Within sample precision for each parameter measured in capillary mode per site, if applicable (at least 15 degrees of freedom shall be obtained for the estimate to be statistically meaningful).

    Time frame: 1 hour

Sponsors and collaborators

Lead sponsor

Radiometer Medical ApS

Industry

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Dec 29, 2025
Registry last updated
Mar 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.